Physician profile
Patrick S Duffy
NPI 1780748368
$6,670.87
in general payments reported to CMS, 2019-2025
22 companies · $2,911 in 2025
The $2,911 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $724 · 2023: $1,701 · 2024: $917 · 2025: $2,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,068 · Education: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,067.86 |
| Education | $460.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,577.86 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $998.52 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $620.32 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $599.08 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $488.55 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $357.34 | 2023 | Vtama |
| Genzyme Corporation | $283.71 | 2021-2025 | |
| Medtronic, INC. | $267.64 | 2025 | Solitaire X, Axium Primetm, Strata |
| Ucb, INC. | $256.81 | 2021-2025 | Bimzelx |
| Amgen INC. | $243.99 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $191.41 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Novartis Pharmaceuticals Corporation | $185.54 | 2021-2025 | |
| Pfizer INC. | $146.46 | 2022-2025 | |
| Incyte Corporation | $108.31 | 2022-2025 | Opzelura |
| Genentech USA, INC. | $102.12 | 2021-2025 | Xolair |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $85.78 | 2025 | Nemluvio |
| Csl Behring | $31.17 | 2024 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.10 | 2023 | Spevigo |
| Astrazeneca Pharmaceuticals LP | $27.73 | 2025 | Fasenra |
| Grifols USA, LLC | $26.11 | 2025 | Xembify |
| Sandoz INC. | $23.57 | 2024 | Hyrimoz |
| Almirall LLC | $18.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Duffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.